Meeting
2022 ASCO Annual Meeting
Association between body mass index and treatment efficacy with immune checkpoint inhibitor therapy: A retrospective study.
Authors
Hannah Wang
Baylor College of Medicine, Houston, TX
Hannah Wang , Atif Ali , Lyndsey L Prather , Wendy Du , Nan Chen , Aakash Sheth , Vlad Sandulache , Anita Lyn Sabichi , Daniel Ying Wang , Jan Ole Kemnade
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2598)
DOI
10.1200/JCO.2022.40.16_suppl.2598
Abstract #
2598
Poster Bd #
253
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: David Lynn
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
First Author: Karen Kelly
Poster
2020 ASCO Virtual Scientific Program
FDA analysis: Impact of BMI on efficacy outcomes in multiple myeloma trials.
First Author: Rachel Ershler